Reading Time: < 1 minuteGosh, it’s been a busy few weeks! Our news cycle has been dominated by Lykos Therapeutics-related
Reading Time: < 1 minuteNext week, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) will meet to discuss Lykos Therapeutics’
Reading Time: 4 minutesWalter Dunn begins by asking two questions of the agency. The first draws on the
Reading Time: < 1 minuteYesterday, ICER’s independent appraisal committee, the New England Comparative Effectiveness Public Advisory Council (NE-CEPAC) met
Reading Time: < 1 minuteLive Coverage Announcement: We will be covering next Tuesday’s Advisory Committee meeting live on Psychedelic
Reading Time: < 1 minuteGeneral Overview A CaaMTech & ASRI Collaboration GH Research & Beckley Psytech: An Update CaaMTech
Reading Time: 2 minutesDespite efforts by the bill’s authors and advocates to play to the tune of state
Reading Time: 2 minutesFeatured content in this Issue: Tempering Excitement Around Recent Raises Compass Shares Cut of Open-Label
Reading Time: < 1 minuteAbbVie has become the latest large pharmaceutical company to dip its toes into neuroplastogen research
Reading Time: < 1 minuteOn Tuesday, Dr. Steffen Thirstrup, Chief Medical Officer (CMO) of the European Medicines Agency (EMA),